Reading CNTA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CNTA free→Reading CNTA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CNTA free→QuarterlyIQ Insights · CNTA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. Court Sanction Hearing Timing and Attendance The hearing at which the Court will be asked to sanction the Scheme of Arrangement (the “Court Sanction Hearing”) is currently scheduled for June 22, 2026 and will be held at The Royal Courts of Justice, The Rolls Building, 7 Rolls Buildings, London EC4A 1NL, United Kingdom. Details of the Court Sanction Hearing will be available on the Court service website on the day before the Court Sanction Hearing. Holders of ordinary shares in t…
Other Events. At 11:59 p.m. on May 21, 2026, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), expired with respect to the previously announced acquisition (the “Acquisition”) of the entire issued and to be issued share capital of Centessa Pharmaceuticals plc, a public limited company registered in England and Wales (the “Company” or “Centessa”) by Eli Lilly and Company (“Parent” or “Lilly”), by means of a court-sanctione…
Entry into a Material Definitive Agreement. Transaction Agreement On March 31, 2026, Centessa Pharmaceuticals plc, a public limited company registered in England and Wales (the “Company”), entered into a Transaction Agreement (the “Transaction Agreement”) with Eli Lilly and Company, an Indiana corporation (“Parent”), and LDH XV Corporation, a Delaware corporation and direct wholly owned subsidiary of Parent (“Purchaser”). Under the terms of the Transaction Agreement, Purchaser (and/or at Pare…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, effective January 1, 2026, Saurabh Saha, M.D., Ph.D., stepped down from his position as Chief Executive Officer and a member of the Board of Directors of Centessa Pharmaceuticals plc (the “Company” or “Centessa”). In connection with his appointment as advisor to the CEO, on February 9, 2026, the Company entered into an Advi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported in the Original Form 8-K, Dr. Mario Alberto Accardi, PhD was appointed as Chief Executive Officer and member of the Board of Directors of the Company, effective January 1, 2026. In connection with this appointment, on January 5, 2026, the Company and Dr. Accardi entered into an Employment Agreement (the “Employment Agreement”…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Executive Officer On December 11, 2025, Centessa Pharmaceuticals plc (the “Company” or “Centessa”) announced the appointment of Dr. Mario Alberto Accardi, PhD, President and founder of the Company’s Orexin Program, as Chief Executive Officer (“CEO”) and member of the Board of Directors (the “Board”), effective January 1, 2026 (…
Other Events. On November 24, 2025, Centessa Pharmaceuticals plc (the “Company”) entered into an Amended and Restated Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink”), which amended and restated that certain Sales Agreement, dated as of January 27, 2023, by and between the Company and Leerink (the “Original Sales Agreement”). Pursuant to the Sales Agreement, the Company may, from time to time in its sole discretion, issue and sell through Leerink, acting as the Co…
Entry into a Material Definitive Agreement. On November 11, 2025, Centessa Pharmaceuticals plc (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 11,627,907 American Depositary Shares (the “ADSs”), each presenting one ordinary share, with a nomina…
Results of Operations and Financial Condition. On November 5, 2025, Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On August 12, 2025, Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Accounting Officer On May 27, 2025, Centessa Pharmaceuticals plc (the “Company”) appointed Raphael Deferiere, CPA, as the Company’s Chief Accounting Officer and designated him as the Company’s principal accounting officer, each effective as of May 27, 2025. Mr. Deferiere assumes the designation of principal accounting officer f…
Results of Operations and Financial Condition. On May 14, 2025, Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the three months ended March 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Results of Operations and Financial Condition. On March 24, 2025, Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter and year ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act…
Entry into a Material Definitive Agreement. On February 14, 2025, Centessa Pharmaceuticals (UK) Limited (“Centessa”), a wholly-owned subsidiary of Centessa Pharmaceuticals plc (the “Company”), entered into a License Agreement (the “License Agreement”) with Genmab A/S (“Genmab”) pursuant to which Centessa granted to Genmab an exclusive worldwide license to leverage the Company’s proprietary LockBody platform to research products against up to three undisclosed targets during a multi-year resea…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.